Johns Hopkins is getting involved with the vast and swiftly growing field of psychedelic research.
The prestigious university is throwing down $17 million from a group of private donors on its Center for Psychedelic and Consciousness Research. It’s the first of its kind the United States and the largest in the world — intended to expand our knowledge and our minds through psychedelic research.
Hopkins Medicine will explore use of psilocybin to treat diseases such as opioid addiction, Alzheimer’s disease, eating disorders, depression and chronic Lyme disease.
The most exciting is the potential that a psychedelic treatment model may have, particularly when treating clinical conditions for which we don’t have effective treatments. — Charles Grob, Professor of Psychiatry and Pediatrics at UCLA’s David Geffen School of Medicine.
Johns Hopkins’ newfound Center not only sets expectations high for psychedelic insights and advancements, it validates the importance of this type of research.
When centers like Hopkins attract this money, it’s a validation of the field as being legitimate. — Charles Nichols, a professor in the Department of Pharmacology and Experimental Therapeutics at LSU Health Medical Center